using antigen-specific, antibody-bound microbeads (Mittenyi Biotech, Survey, UK) on an AutoMacs cell separator (Mittenyi Biotech). In addition, haematopoietic progenitor cell-derived colonies were generated from BM aspirate low-density cells. Cultures were supplemented with granulocyte-macrophage colony-stimulating factor (GM-CSF) alone, GM-CSF with Epo and GM-CSF, Epo IL-3 and stem cell factor. Individual colonyforming units granulocyte/macrophage (CFU-GM)-derived colonies from GM-CSF-supplemented and fully supplemented cultures were harvested for JAK2 analysis by polymerase chain reaction (PCR). For PCR performed on haematopoietic colonies, colonies were placed directly into the PCR reaction without prior DNA extraction. Cell separation kits were used according to the manufacturer's instructions. The presence of the mutant JAK2 allele was detected using an allele-specific PCR (AS-PCR). 4 The presence of the mutation and the ratio of mutant to wildtype JAK2 allele were confirmed by pyrosequencing. Polymerase chain reaction products were generated using the AS-PCR primer sequences. Sequences were read from a reverse sequencing primer 5 0 -TCTCGTCTCCACAGA-3 0 . Pyrosequencing reactions were run on a Biotage PSQ HS 96 pyrosequencer.
The presence of the mutation and the ratio of mutant to wildtype JAK2 allele were confirmed by pyrosequencing. Polymerase chain reaction products were generated using the AS-PCR primer sequences. Sequences were read from a reverse sequencing primer 5 0 -TCTCGTCTCCACAGA-3 0 . Pyrosequencing reactions were run on a Biotage PSQ HS 96 pyrosequencer.
Allele-specific polymerase chain reaction was used to detect the JAK2 V617F mutation in whole-blood, sub-fractionated BM and CFU-GM-derived haematopoietic colonies. The presence of the JAK2 V617F mutation was detected in whole peripheral blood and BM and was also found in all BM cell lineages with the exception of the lymphoid compartment (CD3-and CD19-positive cells). Day 14 cultures contained only CFU-GM-derived colonies. BFU-E-derived and mixed lineage colonies were not detected. All colonies picked and amplified by AS-PCR were positive for the V617F mutation (data not shown). Pyrosequencing of subfractionated BM cells confirms the presence of the JAK2 mutation in CD14-, CD15-, CD34-, CD61-and GPApositive cells and its absence in CD3-and CD19-positive cells ( Figure 1 ). In addition, homo/heterozygosity calling by the Biotage software indicates that the mutation is homozygous and that the BM subcellular fractions are almost 100% clonal with respect to the JAK2 mutant allele.
Two other cases have recently described the concurrent presence of the JAK2 V17F mutation in the context of CNL with one case diagnosed with concurrent B-cell non-Hodgkin's lymphoma. 7, 8 Both case reports described the homozygous presence of the JAK2 mutation within granulocytes as observed in our case. In addition, we have also performed a lineagespecific analysis and our data demonstrate that the mutation is present in all myeloid and erythroid cells tested, but is absent from the lymphoid compartment. We have also found homozygous-mutated JAK2 present in 100% of CFU-GM-derived haematopoietic colonies. These observations concur with separate studies on patients with MPDs, which have shown that the JAK2 mutation is likely to occur as a myeloid lineage-specific mutation.
It remains unclear as to how a single somatic mutation can give rise to such a heterogeneous clinical presentation, and it seems likely that additional changes in either the signalling cascade or other genetic alterations may contribute to the disease phenotype. Our report adds to the observation that JAK2 mutation is not an infrequent event in CNL. All patients with newly diagnosed CNL should be screened to determine the true incidence of the mutation. Given the poor outcome of this disease, patients with CNL and JAK2 mutation should be considered as potential candidates for molecular-targeted therapy. The human Hox genes are a large gene family, consisting of 39 members, which are all located in four gene clusters (HoxAHoxD). They each encode homeodomain containing transcription factors, which are known to be key regulators of embryonic development. 1 The Hox genes are also expressed in adult cells where they play important roles in the control of cellular differentiation, particularly during haematopoiesis. 2 
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Letters to the Editor gene family members (particularly those in the 5 0 end of clusters, paralogs 9-13) are involved in leukaemia-associated translocations 2 and aberrant expression of Hox genes is a common event in leukaemogenesis. Indeed overexpression of multiple Hox genes (particularly within the HoxA cluster) has been identified in both lymphoid and myeloid malignancies. 2 Although the potential mechanisms leading to increased Hox gene expression have been widely studied, aberrant suppression of Hox genes (which are expressed in normal haematopoietic progenitors) has received little attention. Alterations in the patterns of DNA methylation are critical in the development of all types of cancer, 3 and transcriptional repression owing to hypermethylation of promoter-associated CpG islands has been shown to inactivate many genes whose downregulation is known to be important in tumour development, both in haematological malignancies and in solid tumours. 4, 5 All but one of the HoxA cluster genes (HoxA3) have CpG islands associated with their transcriptional start site (sequence derived from clones RP1-170O19 (AC004080), CTD-2536K9 (AC010990), RP1-167F23 (AC004079) in GenBank), suggesting that altered DNA methylation is a potential candidate mechanism for altered Hox gene expression in leukaemia.
We chose to investigate the methylation status of the HoxA4 gene, which is the most 3 0 HoxA gene previously identified as expressed in haematopoietic progenitor cells. 6 Although Hox genes at the 5 0 end of the cluster, particularly HoxA9, have been implicated as oncogenes, 7 the role of the more 3 0 genes is less clear. Initially, a test panel of 21 chronic lymphocytic leukaemia (CLL) samples were analysed for HoxA4 methylation using the COBRA assay, which allows semiquantitative assessment of methylation levels at specific CpG sites (the percentage of COBRA PCR product digested in this assay is equivalent to the percentage of methylated DNA in the sample). Quantitation of methylation levels was carried out by measurement of methylated and unmethylated band intensities using the GeneTools system (Syngene). The values were then corrected for the smaller size (and thus lower ethidium bromide binding capacity) of the methylated band and plotted against those obtained using samples, derived from in vitro methylated DNA, of known methylation status (100, 66 and 33% methylated controls were used). To account for potential variation in the methylation levels across the CpG island, two sets of primers, mapping immediately upstream and downstream of the transcriptional start site (upstream primers: forward, 5 0 -gaggattta tagtttgatagggtttg-3 0 , reverse, 5 0 -ctatcaaatacccactcctcc-3 0 , and downstream primers: forward, 5 0 -tacacttcacaaattaataaccataaa ctc, reverse, 5 0 -gttgttgtagyggtaggtgttg-3 0 ), were used and a total of eight CpG sites assessed using multiple enzyme digests of the COBRA PCR products (HinFI, TaqI and RsaI for upstream primers and HinFI and TaqI for downstream primers). Samples were deemed to be hypermethylated if significant levels of methylation (50% or greater) were identified at multiple CpG sites. This cutoff was applied to exclude samples in which most alleles were unmethylated or in which methylation was only detected at a single CpG site, as such methylation may not significantly alter overall levels of HoxA4 expression. Although no methylation of HoxA4 was detected in normal purified B-lymphocytes (or in peripheral blood (data not shown)), this analysis identified frequent hypermethylation of the HoxA4 gene in CLL samples with seven out of the 21 samples (33%) exhibiting CpG island hypermethylation. Furthermore, methylation of HoxA4 was more frequent in patients with an absence of mutation in the IgVh (immunoglobulin variable heavy chain) region, known to be a poor prognostic indicator, than in patients with IgVh mutation (P ¼ 0.025, examples in Figure 1) . Therefore, to more clearly determine the role of HoxA4 hypermethylation in CLL, the analysis was expanded by examining a further set of 130 samples. This analysis confirmed the presence of frequent HoxA4 hypermethylation in CLL patients (38% (50/130) of samples were hypermethylated, examples in Figure 1 ). In addition, 40 of the samples (20 defined as methylated and 20 as unmethylated) were further assessed for HoxA4 methylation using pyrosequencing analysis. As shown in Table 1 , this analysis confirmed the results of the COBRA assays, with very high levels of methylation detected in all the methylated samples, whereas no or low levels of methylation were detected in the unmethylated samples. These results suggest that aberrant DNA methylation may have a major role in the control of HoxA4 gene expression in CLL. To confirm that hypermethylation of the HoxA4 CpG island was associated with reduced gene expression, RNA was extracted from 26 of Hypermethylation of the HoxA4 CpG island correlates with loss of gene expression. Real time qRT-PCR analysis (using the DyNAmo SYBR Green qPCR kit (Finnzymes) and an Opticon 2 DNA engine (MJ Research)) was used to determine the HoxA4 expression level of samples with and without HoxA4 hypermethylation. Samples lacking HoxA4 hypermethylation (left hand side) exhibit far higher levels of expression than samples with HoxA4 hypermethylation (right hand side). HoxA4 expression was normalized to B2-microglobulin expression and expression levels are expressed relative to HoxA4 expression in B-lymphocytes, purified from normal peripheral blood (given the arbitrary value of 1).
Letters to the Editor the CLL samples and used for real-time qRT-PCR. In samples lacking HoxA4 CpG island hypermethylation, high levels of HoxA4 expression, comparable to those detected in purified peripheral blood B-lymphocytes, was detected in nearly all (11/12) samples. In contrast HoxA4 expression was low or undetectable in all 14 of the samples that exhibited hypermethylation of HoxA4, indicating that HoxA4 hypermethylation was strongly correlated with the loss of expression (Figure 2 , P ¼ 0.000002, Fisher exact test).
As with the initial analysis, HoxA4 methylation was again associated with lack of IgVh mutation in the patients (P ¼ 0.016) and overall the frequency of HoxA4 hypermethylation was much greater in unmutated cases (25/44, 57%) than in samples from patients with mutated IgVh (32/107, 30%). Consistent with this observation, patients with HoxA4 hypermethylation exhibited a trend towards reduced survival (median survival 159 versus 199 months in hypermethylated and non-hypermethylated patients, respectively), although this failed to reach statistical significance.
The results presented here represent the first report of DNA methylation-dependent downregulation of a Hox gene in human leukaemia. As HoxA cluster gene expression is thought to be crucial in haematopoiesis 2 and all but one of the HoxA cluster genes have promoter-associated CpG islands, further analysis will be required to determine whether further HoxA genes show DNA methylation-dependent effects on gene expression. We are currently examining the role of DNA methylation at other HoxA cluster genes in both lymphoid and myeloid malignancies.
HoxA4 expression has been detected in normal haematopoietic progenitor cells, 6 suggesting a potential role for HoxA4 in the control of normal differentiation, although little is known about the functional role of HoxA4 in haematopoietic or other cell types. However, consistent with a potential tumour suppressor role for HoxA4, reduced HoxA4 expression has been identified in ulcerative colitis-associated colorectal carcinoma 8 and HoxA4 has been shown to be downregulated by the expression of the oncogene N-ras in teratocarcinoma cells and associated with reduced differentiation capability and increased proliferation. 9 The large number of members in the Hox gene family raises the possibility of functional redundancy, which may limit the impact of loss of a single Hox gene and indeed inactivation of multiple HoxB genes has been shown to be compatible with normal haematopoiesis. 10 In contrast, previous studies have shown that loss of single HoxA cluster genes can have pronounced effects on normal haemotopoiesis [11] [12] [13] This may suggest more important role for the HoxA cluster genes, which are expressed at higher levels in normal haematopoietic progenitors 6 than the HoxB cluster genes. Clearly, the functional role of HoxA4 in CLL, particularly in the poorer prognosis IgVh unmutated cases, is worthy of further study. 0  0  10  3  M1  100  83  100  94  U2  12  9  11  11  M2  100  86  100  95  U3  20  23  23  22  M3  100  87  100  96  U4  0  0  0  0  M4  96  90  100  95  U5  0  0  0  0  M5  92  89  100  94  U6  52  31  34  39  M6  100  84  100  95  U7  0  0  0  0  M7  100  89  100  96  U8  37  28  37  34  M8  100  83  100  94  U9  41  35  46  41  M9  100  91  100  97  U10  24  17  23  21  M10  100  87  100 
